| Metric | Value ($ M) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 271.70 | 22.5% | 8.1% |
| Total Income | 271.70 | 22.5% | 8.1% |
| Expenditure | 223.00 | 19.4% | 10.7% |
| PBT | 27.60 | 190.5% | 61.8% |
| Net Profit | 21.10 | 614.6% | 53.6% |
| OPM | 17.92% | 2.14pp | 13.89pp |
| NPM | 7.77% | 9.62pp | 7.63pp |
| EPS | 0.36 | 614.3% | 53.9% |
Embecta Corp. Reports Q3 FY26 Financial Results
07 Aug 2026 · 7 Aug, 4:42 pm
Summary
Embecta Corp. reported third quarter fiscal year 2026 revenues of $271.7 million, an 8.1% decrease year-over-year. Gross profit declined to $153.3 million with a margin of 56.4%, and net income was $21.1 million, or $0.36 per diluted share. For the nine months ended June 30, 2026, revenues were $754.7 million, down 7.6% year-over-year. Management highlighted sequential improvements in the third quarter due to factors including improved performance in the United States and International segments, as well as contributions from the Owen Mumford acquisition. The company reaffirmed its fiscal year 2026 revenue guidance and raised its outlook for adjusted operating margin and adjusted earnings per share.
Key Highlights
- 1
Embecta Corp. reported third quarter fiscal year 2026 revenues of $271.7 million, a decrease of 8.1% on a reported basis compared to the prior year period.
- 2
Gross profit for the third quarter was $153.3 million with a margin of 56.4%, down from $197.1 million and 66.7% in the prior year period.
- 3
Adjusted operating income for the third quarter was $69.4 million, a decrease from $109.1 million in the prior year period.
- 4
Net income for the third quarter was $21.1 million, or $0.36 per diluted share, compared to $45.5 million, or $0.78 per diluted share, in the prior year period.
- 5
For the nine months ended June 30, 2026, reported revenues were $754.7 million, down 7.6% on a reported basis compared to the prior year period.
- 6
The company reaffirmed its fiscal year 2026 revenue guidance range and raised its full year guidance ranges for adjusted operating margin and adjusted earnings per share.
Management Comments
Devdatt (Dev) Kurdikar
Our third quarter results improved significantly on a sequential basis, with revenue increasing approximately $50 million, GAAP operating income increasing approximately $14 million, and adjusted operating income increasing approximately $21 million as compared to our second quarter results. The sequential increase was due to a combination of factors, including improved performance within the United States and International, as well as contribution from the acquisition of Owen Mumford which closed mid-way through our third quarter. We repaid approximately $53 million of debt during the quarter and also repurchased approximately $9 million of shares under our three-year, up to $100 million share repurchase program. While our GLP-1 B2B partners launched generic GLP-1 therapies co-packaged with our pen needles in Canada and Brazil. Given our year-to-date performance, we are reaffirming our fiscal year revenue guidance range and raising our full year guidance ranges for adjusted operating margin and adjusted earnings per share.
Informational and educational content only. Not investment advice.